|Daily Range||$0.00 - $0.00|
|52-Week Range||$76.89 - $129.25|
|Dividend (Yield)||$0.00 (0.0%)|
|Average Daily Volume||372|
|Current FY EPS||$5.49|
News & Commentary
Here are the reasons behind last week's big move in United Therapeutics (UTHR), Cubist Pharmaceuticals (CBST), and Incyte Corporation (INCY).
Gilead investors should look beyond the company’s antiviral portfolio and take a closer look at these hidden gems in its pipeline, which could shape the company’s long-term future.
The PAH treatment market got more crowded in 2013, suggesting an important battle for market share will be fought in 2014.